Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attact trial (ALLHAT)

Journal of Clinical Hypertension

Volumn 4, Issue 6, 2002, Pages 393-404

  Cushman, William C ^a   Ford, Charles E ^b   Cutler, Jeffrey A ^b   Margolis, Karen L ^b   Davis, Barry R ^b   Grimm, Richard H ^b   Black, Henry R ^b   Hamilton, Bruce P ^b   Holland, Joanne ^b   Nwachuku, Chuke ^b   Papademetriou, Vasilios ^b   Probstfield, Jeffrey ^b   Wright Jr , Jackson T ^b   Alderman, Michael H ^b   Weiss, Robert J ^b   Piller, Linda ^b   Bettencourt, Judy ^b   Walsh, Sandra M ^b  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; CHLORTALIDONE; CLONIDINE; DOXAZOSIN; HYDRALAZINE; LISINOPRIL; RESERPINE;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DEMOGRAPHY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; ETHNOLOGY; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MULTICENTER STUDY; NEGRO; NORTH AMERICA; PREDICTION; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 0036863587     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2002.02045.x     Document Type: Article

References (23)

1. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
2. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
3. Mulrow P. Hypertension: a worldwide epidemic. In. Black HR, Izzo JI Jr, eds. Hypertension Primer, Second Edition, The Essentials of High Blood Pressure. Dallas, TX; American Heart Association; 1999:271-273.
4. Julius S. Worldwide trends and shortcomings in the treatment of hypertension. Am J Hypertens. 2000;13:57S-61S.
5. Meissner I, Whisnant JP, Sheps SG, et al. Detection and control of high blood pressure in the community: do we need a wake-up call? Hypertension. 1999;34:466-471.
6. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:1957-1963.
7. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
8. World Health Organization-International Society of Hypertension Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens. 1999; 17:151-183.
9. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479-486.
10. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975.
11. Davis BR, Cutler JA, Gordon DJ, et al., for the ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342-360.
12. Cutler JA, Gordon DJ, Davis BR, et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). In: Black HR, ed. Clinical Trials in Hypertension. New York, NY. Marcel Dekker; 2001:531-586.
13. Grimm RH, Margolis KL, Papademetriou V, et al., for the ALLHAT Collaborative Research Group. Baseline characteristics of participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2001;37:19-27.
14. Wright JT, Cushman WC, Davis BR, et al., for the ALLHAT Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience. Control Clin Trials. 2001;22:659-673.
15. Pressel S, Davis BR, Louis, GT, et al., for the ALLHAT Research Group. Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. (ALLHAT). Control Clin Trials. 2001;22:674-686.
16. Dunnett CW. A multiple comparisons procedure for comparing several treatments with a control. J Am Stat Assoc. 1955;60:573-583.
17. Black HR, Elliott WJ, Neaton JD, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension. 2001;37:12-18.
18. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
19. Kjeldsen SE, Dahlof B, Devereux RB, et al. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. Am J Hypertens. 2000;13:899-906.
20. Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives. Analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001;37:869-874.
21. Cushman WC, Reda DJ, Perry HM, et al., for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Arch Intern Med. 2000;160:825-831.
22. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci U S A. 1984:81:583-587.
23. Lo CS, Relf IRN, Myers KA, et al. Doppler ultrasound recognition of preclinical changes in arterial wall in diabetic subjects. Diabetes Care. 1986;9:27-31.